Abstract
AbstractCritical challenges remain in clinical translation of extracellular vesicle (EV)-based therapeutics due to the absence of methods to enrich cells with high EV secretion. Current cell sorting methods are limited to surface markers that are uncorrelated to EV secretion or therapeutic potential. We developed a nanovial technology for enrichment of millions of single cells based on EV secretion. This approach was applied to select mesenchymal stem cells (MSCs) with high EV secretion as therapeutic cells for improving treatment. The selected MSCs exhibited distinct transcriptional profiles associated with EV biogenesis and vascular regeneration and maintained high levels of EV secretion after sorting and regrowth. In a mouse model of myocardial infarction, treatment with high-secreting MSCs improved heart functions compared to treatment with low-secreting MSCs. These findings highlight the therapeutic importance of EV secretion in regenerative cell therapies and suggest that selecting cells based on EV secretion could enhance therapeutic efficacy.
Publisher
Cold Spring Harbor Laboratory
Reference34 articles.
1. Mesenchymal stem cell-derived extracellular vesicles for immunomodulation and regeneration: a next generation therapeutic tool?;Cell Death & Disease 2022,2022
2. Extracellular vesicles engineering by silicates-activated endothelial progenitor cells for myocardial infarction treatment in male mice;Nature Communications 2023,2023
3. Regulation of immune responses by extracellular vesicles
4. Native and bioengineered extracellular vesicles for cardiovascular therapeutics;Nature Reviews Cardiology,2020
5. Nikfarjam, S. , Rezaie, J. , Zolbanin, N. M. & Jafari, R . Mesenchymal stem cell derived-exosomes: a modern approach in translational medicine. J Transl Med 18, (2020).